Physician Hesitation to Prescribe Biogen/Eisai's Aduhelm in Alzheimer's Disease Grows Amid Controversies, According to Spherix Global Insights

/PRNewswire/ -- For those of us following the evolution of neurology pharmaceutical markets, 2021 will be remembered by many for the tumultuous roll out of...

Related Keywords

Genentech Morphosys ,Synaptogenix Bryostatin ,Eisai Aduhelm ,Kristen Henn ,Eli Lilly ,Dynamix ,Business Development ,Global Insights ,Launch Dynamix ,Market Dynamix ,Spherix Global Insights ,